

Opinion: Journal of Drug Metabolism and Toxicology

Maria Durisova*

Institute of Experimental Pharmacology and Toxicology, The Slovak Academy of Sciences, Slovakia

*Corresponding author: Maria Durisova, Senior Research Worker, Institute of Experimental Pharmacology and Toxicology, The Slovak Academy of Sciences, Slovakia, Tel: 00421-25477592; E-mail: maria.durisova@savba.sk

Received date: April 22, 2016; Accessed date: April 25, 2016; Published date: April 28, 2016

Copyright: © 2016 Durisova M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

The field of pharmacokinetics still faces considerable scientific challenges especially in the areas of drug metabolism and toxicology.

Therefore, several new methods have gradually emerged in pharmacokinetics, including new methods for mathematical modeling, and the development of mathematical models has become one of the most rapidly growing and exciting application-oriented sub-discipline of pharmacokinetics, especially in studies of drug metabolism and toxicity.

While recent years brought a tremendous progress in the understanding of drug metabolism and toxicity many unresolved issues and questions remain. Therefore, editor hopes that articles published in the Journal of Drug Metabolism & Toxicology will

prompt scientists to solve difficult questions related to drug metabolism and toxicity.

The reviewer worked as a researcher and contractor in the 6FP-Project "Network of Excellence: Biosimulation - A New Tool in Drug Development, contract No. LSHB CT-2004-005137" and in the 7FP-Project "Network of Excellence: Virtual Physiological Human". The reviewer worked also in several previous COST program actions.

At present, the reviewer precipitates: 1) In the Action BM1204 of the COST program entitled: An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease; and 2) In the EuroNanoMed2, an integrated European project.